%PDF-1.4
%
89 0 obj
<>
endobj
86 0 obj
<>
endobj
162 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2004-08-06T15:20:41Z
2024-03-28T13:43:46-07:00
QuarkXPressª 4.11: AdobePS 8.8.0 (301)
2024-03-28T13:43:46-07:00
application/pdf
Heather
2003-344.sept
uuid:bbf2c2a2-1dd1-11b2-0a00-1f09276d7200
uuid:bbf2c2a4-1dd1-11b2-0a00-b80000000000
endstream
endobj
75 0 obj
<>
endobj
76 0 obj
<>
endobj
90 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 55 0 R/Type/Page>>
endobj
1 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 57 0 R/Type/Page>>
endobj
4 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 59 0 R/Type/Page>>
endobj
7 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 61 0 R/Type/Page>>
endobj
15 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 63 0 R/Type/Page>>
endobj
23 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 65 0 R/Type/Page>>
endobj
31 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 67 0 R/Type/Page>>
endobj
44 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 69 0 R/Type/Page>>
endobj
192 0 obj
[196 0 R]
endobj
193 0 obj
<>stream
q
0 0 612 783 re
W n
BT
0.85091 0.85091 0.85091 rg
/T1_0 19 Tf
0.6283 0.7779 -0.7779 0.6283 8.2321 49.765 Tm
(Personal non-commercial use only. The Journal of Rheumatology. Copyright\
\251 2004. All rights reserved)Tj
ET
Q
1 g
/GS0 gs
0 783 m
0 783 l
f
q
-1 784 587 -785 re
W n
q
0 783.03 612 -783 re
W n
0 0 0 1 K
/GS1 gs
43 71 m
547 71 l
S
BT
0 0 0 1 k
/T1_1 1 Tf
-0.00011 Tc 0.02499 Tw 8 0 0 8 43.5 52.9843 Tm
[(Y)91.8 (oo: Lipid pr)36.8 (ofile in active RA)]TJ
0 Tc 0 Tw 60.9375 -0.0313 Td
(1753)Tj
/T1_2 1 Tf
-0.00011 Tc 0.06441 Tw 10 0 0 10 43 730.1616 Tm
[(factors that af)17.7 (fect lipid profiles were excluded. However)39.7 (, a)]TJ
-0.0126 Tw 0 -1.2 TD
[(lar)17.7 (ge number of exclusion criteria in patients with RA)-182.6 (might)]TJ
0.2077 Tw T*
(limit description of real lipid profiles in the general RA)Tj
0 Tw T*
(population.)Tj
0.04179 Tw 1.2 -1.2 Td
[(In conclusion, patients with active RA)-237.1 (have altered lipid)]TJ
0.14819 Tw -1.2 -1.2 Td
(profiles, and these abnormal patterns, associated with sex)Tj
0.21291 Tw T*
(and menopause status, would be expected to change the)Tj
0.0757 Tw T*
[(pattern of atherosclerotic events in RA. Further lar)17.7 (ge-scale)]TJ
0.3336 Tw T*
[(studies are warranted to define the ef)17.7 (fects of sex and)]TJ
-0.036 Tw T*
(menopausal status on lipoprotein and apolipoprotein activity)Tj
0.0139 Tw T*
[(in RA. It is also necessary to consider the ef)17.7 (fects of sex and)]TJ
0.0152 Tc 0.3597 Tw T*
(menopausal status in studies of lipid profiles in the)Tj
-0.00011 Tc 0.02499 Tw T*
(rheumatic diseases.)Tj
/T1_3 1 Tf
0 Tw 0 -2.4 TD
(REFERENCES)Tj
/T1_2 1 Tf
0.02499 Tw 8 0 0 8 50 552.1616 Tm
[(1.)-875.1 (Isomaki HA, Mutru O, Koota K. Death rate and causes of death in)]TJ
1.675 -1.25 Td
(patients with rheumatoid arthritis. Scand J Rheumatol )Tj
0 Tc 0 Tw 0 -1.25 TD
(1975;4:205-8.)Tj
-0.00011 Tc 0.02499 Tw -1.675 -1.25 Td
[(2.)-875.1 (Mutru O, Laakso M, Isomaki H, Koota K. )17.7 (T)69.9 (en year mortality and)]TJ
1.675 -1.25 Td
(causes of death in patients with rheumatoid arthritis. BMJ \(Clin Res)Tj
T*
(Ed\) 1985;290:1797-9.)Tj
-1.675 -1.25 Td
[(3.)-875.1 (W)79.9 (atson DJ, Rhodes )17.7 (T)74 (,)-0.1 ( Guess HA. )54.8 (All-cause mortality and vascular)]TJ
1.675 -1.25 Td
(events among patients with rheumatoid arthritis, osteoarthritis, or)Tj
T*
(no arthritis in the UK General Practice Research Database. )Tj
T*
[(J Rheumatol 2003;30:1)36.8 (196-202.)]TJ
-1.675 -1.25 Td
[(4.)-875.1 (Pinals RS. Survival in rheumatoid arthritis. )54.8 (Arthritis Rheum)]TJ
0 Tc 0 Tw 1.675 -1.25 Td
(1987;30:473-5.)Tj
-0.00011 Tc 0.02499 Tw -1.675 -1.25 Td
[(5.)-875.1 (Mitchell DM, Spitz PW)91.7 (, )36.8 (Y)99.8 (oung DY)128.8 (, Bloch DA, McShane DJ, Fries)]TJ
1.675 -1.25 Td
[(JF)79.7 (. Survival, prognosis, and causes of death in rheumatoid arthritis.)]TJ
T*
(Arthritis Rheum 1986;29:706-14.)Tj
-1.675 -1.25 Td
[(6.)-875.1 (V)110.8 (an Doornum S, McColl G, )17.7 (W)39.8 (icks IP)110.7 (. Seropositive rheumatoid)]TJ
1.675 -1.25 Td
[(arthritis in Northern Sweden. )54.8 (Arthritis Rheum 2002;46:862-73.)]TJ
-1.675 -1.25 Td
[(7.)-875.1 (Goodson N. Coronary artery disease and rheumatoid arthritis. Curr)]TJ
1.675 -1.25 Td
[(Opin Rheumatol 2002;14:1)36.8 (15-20.)]TJ
-1.675 -1.25 Td
[(8.)-875.1 (Park )36.8 (YB, )54.8 (Ahn CW)91.7 (, Choi HK, et al. )54.8 (Atherosclerosis in rheumatoid)]TJ
1.675 -1.25 Td
(arthritis: morphologic evidence obtained by carotid ultrasound.)Tj
T*
(Arthritis Rheum 2002;46:1714-9.)Tj
-1.675 -1.25 Td
[(9.)-875.1 (Castelli )17.7 (WP)110.7 (, Garrison RJ, )17.7 (W)39.9 (ilson PW)91.7 (, )54.8 (Abbott RD, Kalousdian S,)]TJ
1.675 -1.25 Td
[(Kannel )17.7 (WB. Incidence of coronary heart disease and lipoprotein)]TJ
T*
[(cholesterol levels. )17.7 (The Framingham Study)64.8 (. JAMA)]TJ
0 Tc 0 Tw T*
(1986;256:2835-8.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(10.)-875.1 (Kannel )17.7 (WB, Neaton JD, )17.7 (W)79.9 (entworth D, et al. Overall and coronary)]TJ
2.175 -1.25 Td
(heart disease mortality rates in relation to major risk factors in)Tj
T*
[(325,348 men screened for the MRFIT)73.9 (. Multiple Risk Factor)]TJ
T*
[(Intervention )17.7 (T)35 (rial. )54.8 (Am Heart J 1986;1)36.8 (12:825-36.)]TJ
-2.1381 -1.25 Td
[(1)36.8 (1)-0.1 (.)-875.1 (Manninen )17.7 (V)128.9 (, Elo MO, Frick MH, et al. Lipid alterations and decline)]TJ
2.1381 -1.25 Td
(in the incidence of coronary heart disease in the Helsinki Heart)Tj
0 Tc T*
[(Study)64.9 (. JAMA)-220.1 (1988;260:641-51.)]TJ
-0.00011 Tc -2.175 -1.25 Td
[(12.)-875.1 (London MG, Muirden KD, Hewitt JV)128.8 (. Serum cholesterol in)]TJ
2.175 -1.25 Td
(rheumatic diseases. BMJ 1963;1:1380-3.)Tj
-2.175 -1.25 Td
[(13.)-875.1 (Rossner S, Lofmark C. Dyslipoproteinaemia in patients with active,)]TJ
2.175 -1.25 Td
[(chronic polyarthritis. )54.8 (A)-220.1 (study on serum lipoproteins and triglyceride)]TJ
T*
[(clearance \(intravenous fat tolerance test\). )54.8 (Atherosclerosis)]TJ
0 Tc 0 Tw T*
(1977;28:41-52.)Tj
-0.00011 Tc 0.02499 Tw 30.825 69.921 Td
[(14.)-875.1 (Lorber M, )54.8 (A)74 (viram M, Linn S, Scharf )36.8 (Y)128.9 (,)-0.1 ( Brook JG.)]TJ
2.175 -1.25 Td
(Hypocholesterolaemia and abnormal high-density lipoprotein in)Tj
T*
(rheumatoid arthritis. Br J Rheumatol 1985;24:250-5.)Tj
-2.175 -1.25 Td
[(15.)-875.1 (Frati E, Castagna ML, Bacarelli MR, et al. Plasma levels of)]TJ
2.175 -1.25 Td
(apolipoprotein and HDL-cholesterol in patients with rheumatoid)Tj
T*
(arthritis. Boll Soc Ital Biol Sper 1984;60:1791-6.)Tj
-2.175 -1.25 Td
[(16.)-875.1 (Dahlen GH. Lp\(a\) lipoprotein in cardiovascular disease.)]TJ
2.175 -1.25 Td
[(Atherosclerosis 1994;108:1)36.8 (1)36.8 (1-26.)]TJ
-2.175 -1.25 Td
[(17.)-875.1 (Maeda S, )54.8 (Abe )54.8 (A, Seishima M, Makino K, Noma )54.8 (A, Kawade M.)]TJ
2.175 -1.25 Td
[(T)35 (ransient changes of serum lipoprotein\(a\) as an acute phase)]TJ
-0.0298 Tw T*
[(protein. Atherosclerosis )-54.8 (1989;78:145-50.)]TJ
0.02499 Tw -2.175 -1.25 Td
[(18.)-875.1 (Lazarevic MB, )17.7 (V)59.8 (itic J, Mladenovic )17.7 (V)128.9 (,)-0.1 ( Myones BL, Skosey JL,)]TJ
2.175 -1.25 Td
[(Swedler )17.7 (WI. Dyslipoproteinemia in the course of active rheumatoid)]TJ
T*
[(arthritis. Semin )54.8 (Arthritis Rheum 1992;22:172-8.)]TJ
-2.175 -1.25 Td
[(19.)-875.1 (Park )36.8 (YB, Lee SK, Lee )17.7 (WK, et al. Lipid profiles in untreated)]TJ
2.175 -1.25 Td
(patients with rheumatoid arthritis. J Rheumatol 1999;26:1701-4.)Tj
-2.175 -1.25 Td
[(20.)-875.1 (Rantapaa-Dahlqvist S, )17.7 (W)79.9 (allber)17.7 (g-Jonsson S, Dahlen G. Lipoprotein)]TJ
2.175 -1.25 Td
(\(a\), lipids, and lipoproteins in patients with rheumatoid arthritis.)Tj
0 Tc T*
(Ann Rheum Dis 1991;50:366-8.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(21.)-875.1 (Li Z, McNamara JR, Fruchart JC, et al. Ef)17.7 (fects of gender and)]TJ
2.175 -1.25 Td
(menopausal status on plasma lipoprotein subspecies and particle)Tj
T*
(sizes. J Lipid Res 1996;37:1886-96.)Tj
-2.175 -1.25 Td
[(22.)-875.1 (Anderson KM, Castelli )17.7 (WP)110.7 (, Levy D. Cholesterol and mortality)64.8 (. 30)]TJ
2.175 -1.25 Td
[(years of follow-up from the Framingham Study)64.8 (. JAMA)]TJ
0 Tc 0 Tw T*
(1987;257:2176-80.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(23.)-875.1 (Brown SA, Hutchinson R, Morrisett J, et al. Plasma lipid, )]TJ
2.175 -1.25 Td
(lipoprotein cholesterol, and apoprotein distributions in selected US)Tj
T*
[(communities. )17.7 (The )54.8 (Atherosclerosis Risk in Communities \(ARIC\))]TJ
-0.0298 Tw T*
[(Study)64.8 (. Arterioscler )-37.1 (Thromb )-54.8 (1993;13:1)36.8 (139-58.)]TJ
0.02499 Tw -2.175 -1.25 Td
[(24.)-875.1 (Stevenson JC, Crook D, Godsland IF)79.7 (. Influence of age and)]TJ
2.175 -1.25 Td
(menopause on serum lipids and lipoproteins in healthy women.)Tj
T*
(Atherosclerosis 1993;98:83-90.)Tj
-2.175 -1.25 Td
[(25.)-875.1 (Razay G, Heaton KW)91.7 (, Bolton CH. Coronary heart disease risk)]TJ
2.175 -1.25 Td
(factors in relation to the menopause. Q J Med 1992;85:889-96.)Tj
-2.175 -1.25 Td
[(26.)-875.1 (Arnett FC, Edworthy SM, Bloch DA, et al. )17.7 (The )54.8 (American)]TJ
2.175 -1.25 Td
[(Rheumatism )54.8 (Association 1987 revised criteria for the classification)]TJ
T*
[(of rheumatoid arthritis. )54.8 (Arthritis Rheum 1988;31:315-24.)]TJ
-2.175 -1.25 Td
[(27.)-875.1 (Allain CC, Poon LS, Chan CS, Richmond )17.7 (W)91.8 (, Fu PC. Enzymatic)]TJ
2.175 -1.25 Td
(determination of total serum cholesterol. Clin Chem 1974;20:470-5.)Tj
-2.175 -1.25 Td
[(28.)-875.1 (Friedewald )17.7 (WT)73.9 (, Levy RI, Fredrickson DS. Estimation of the)]TJ
2.175 -1.25 Td
(concentration of low-density lipoprotein cholesterol in plasma,)Tj
T*
(without use of the preparative ultracentrifuge. Clin Chem)Tj
0 Tc 0 Tw T*
(1972;18:499-502.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(29.)-875.1 (Ross R. )54.8 (Atherosclerosis \321 an inflammatory disease. N Engl J Med)]TJ
0 Tc 0 Tw 2.175 -1.25 Td
[(1999;340:1)36.9 (15-26.)]TJ
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(30.)-875.1 (Dessein PH, Stanwix )54.8 (AE, Jof)17.7 (fe BI. Cardiovascular risk in )]TJ
2.175 -1.25 Td
(rheumatoid arthritis versus osteoarthritis: acute phase response)Tj
T*
(related decreased insulin sensitivity and high-density lipoprotein)Tj
T*
(cholesterol as well as clustering of metabolic syndrome features in)Tj
T*
[(rheumatoid arthritis. )54.8 (Arthritis Res [Internet] 2002; [cited May 12,)]TJ
T*
[(2004] 4:R5. )54.8 (A)74 (vailable from: http://arthritis-)]TJ
0 Tw T*
(research.com/content/4/5/R5)Tj
0.02499 Tw -2.175 -1.25 Td
[(31.)-875.1 (Cutolo M, Seriolo B, )17.7 (V)59.8 (illaggio B, Pizzorni C, Craviotto C, Sulli )54.8 (A.)]TJ
2.175 -1.25 Td
(Androgens and estrogens modulate the immune and inflammatory)Tj
T*
[(responses in rheumatoid arthritis. )54.8 (Ann NY)-183.3 (Acad Sci )]TJ
0 Tc 0 Tw T*
(2002;966:131-42.)Tj
ET
0 0 0 0 k
/GS0 gs
96.22 75.74 396.48 -10.83 re
f*
0.5 w
96.22 75.74 396.48 -10.83 re
S
Q
Q
q
0 0 612 783 re
W n
BT
0 0 0 rg
/GS2 gs
/T1_4 8 Tf
110.368 69 Td
(Personal, non-commercial use only. The Journal of Rheumatology. Copyri\
ght \251 2004. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_5 1 Tf
10 0 0 10 540 8 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-16.72996 0 Td
(Downloaded on March 28, 2024 from )Tj
ET
endstream
endobj
69 0 obj
<>stream
8;Z\6!HQ(3#ikq,j?%,r5f1OGdjDbF(Tt6T4c4rT79&aNjWQ+WfCR8Is"dt'Mp+K^
Y7@,7+,3JV^%g=kk?D50D+`8TR_+J6WI(At,5[_I\GPJ9$':P74t
SEIbD7h_NIU@hFU7NcR)OTM[pOU`;#CXjGb\(-:[=0n]_\HSYB,/;iVnB_deX76lq
hoW=!!?aT[!nQZ^F,n$$k-SCmtD(4IY3#lqS:1P@]+&oY2
-5B<\"TSE3Q$NgJe8ZGjKFkPQF#)%&ZBDG-l%a%C>"'=pZnuIGo"C[sO:mTMf1P0G
GMM`?64V$b7E-Y
endstream
endobj
73 0 obj
[/Indexed/DeviceRGB 255 72 0 R]
endobj
72 0 obj
<>stream
J,g]g+e/h_!_gCtO=0f)$P%cIi8Zdfc5&3j_8$7g.@L`YKUJNGBP\poR=_;Dl'P(T
(7Boo^^S:71(MN]ZQX/+Cbu.lK"p74pe1T%s.DY%&\1TdJhr54.M9au6>79n6`Q:4
PbLSZTLEE(8E@'*1mg_*eTnN*;*'V3+gm-EEetX%;Bo$ur2ss*N`.-!.kG_q6GDD'
dKoL!8Ka#EV,@V!\j8ZFbp6EE<9cn=N6j0nf;(&;QU6bUD')c@\
9-d\DA=cZ0Q>gIM$$;cd2O@&a;X,Nn_aP(]I1aRc(K1^ue>
gF/(+GaKo$qneLWDrQ#;5\S(\$q'4Q,85`-8;S(=Z"WSBOV*FM)4,?B],R
endstream
endobj
145 0 obj
<>
endobj
92 0 obj
<>
endobj
97 0 obj
<>
endobj
47 0 obj
<>
endobj
128 0 obj
<>
endobj
167 0 obj
<>
endobj
49 0 obj
<>
endobj
50 0 obj
<>stream
HLPw9v_lEY=I1WCiB$gD!Np;;,h= J1
"5*`t1X'TMZC<7cw%8;>yKI1&SVVEeW|V&FBG#dN'ώ9x?~⎐i5:!(:(?dqBB*JYR.<_',IMI|AɏkVS"VUn)s BtrKbAȰل\Kȵ,bzX`u f\4Yb(rvGy"d$E/:DsUluYfjqtWs >s@GđDX#f#"" Dar.YG~%⽈]N#ʤ%z
J~Zܧ)YaS'g4Ãe5ּ]sE"!khSlkcT-N=r"|~[=>JVf KNtBx8%lѶङ/{!b'$''-Nsۯ/,1b '-x-xUxR(܃$e|BCc 9,,NL4sHD}~9c=Ҹ۱5ZGnzߨN@F^%$u-1n揭
o8dazr[@gR(g8+jfl̍EA5:0
OE\j wZ/[0^gԀCOEK(04B
wDfyj<3ܟ@zW/r*d֏!/$锠da=`zNwE4?q!B!8οQ\MkU%H(oq_X^}»HJ
-@
5߆Bj)dȗEh
M_! q*16iLO/W4
}SwU9v1(_GzC|^=*?geؠ^oDxs؆76
Okj^gnGJ 4Vu\eeKA}EC
lf&RYQ,Qw7 `[[3*ObO%膷,@rZ3a;v^ӏygȓ?BN@8We^4/
`5|_$Éx>b>qa>8jYZMHcn0[gi5~~wx=_3쬮kq|@ꁧY%MY.җ|=D6lBr_ڥ䎄g
̴'f؞n >qk#;PV<}ˍg8׆
\J]
^fw>9.fqnmhl;3hr_vzǿF1ג=GG+?(%?% ON/2]܁>MվEu(h?.aTՆpJv2+H﹠X
t:%ŀ"}l52Zm-Zf袷3%,\oƱۇG>[3hhVR4y7\QjZFKɮ&YỤ?UWg+[
` ?kx
endstream
endobj
96 0 obj
<>
endobj
119 0 obj
<>stream
H|UTga2I0QL(@]@Պb(S V
j-|Պv칓hOwΜ?w~wpe8.q2A]K Wͪ?mӋMh A[#x,Z"O)'!)9g@9Ym$+-1ǹ.Nk?Tk2ce+e.7[9+Fw:R!MV$he[UQ$:IvɼesX,IU$29_eJL.KNG+Iq2vJQȼ?UѫI2%ӦDjJyR;?pƸff-b&&lMcVag00#kwG*7Yb`'pb
Q"XXS %L6s<ļM4z篚749/wlY߆ene<˼q݂c-r,Z6!VV!VoTTxH8naۋ,6εm=!
?Opl|d|_K@7@>T~=ѩ)YM⪓U=:)_|
jhvA;DS$rqX"$pW$=#/˟ -vKg¶"OrA2$^%პ^\v|F[ZYDExuX՚G{/i9RiԜ-鋪&O=έo@sDknmn]d&>-llk Д)T]Ej;n6ssu2rjZ{pv7""[ː-CCKdi#{+A9|8=`1Mj ֆmx)ac?<BQ?ZHhр_ 3> fdᕍdpC-L|A!d8"![ h*Isc*"+D9eYg{E8:[=E ~-X]Nnc)ٰ